Home > Insider Trading > Filing (0001104659-22-000976)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1410939	Iveric Bio Inc.	ISEE	Pharmaceutical Preparations (2834)	208185347

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1703623	Francis David Carroll	C/O Iveric Bio, Inc. 5 Penn Plaza, Suite 2372 New York NY 10001	Svp, Cfo And Treasurer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-12-31	32,500	$0.00	81,323	No	4	M	Direct
Common Stock	Disposition	2022-01-03	15,819	$16.39	65,504	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2021-12-31	32,500	$0.00	32,500	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units.
Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on December 31, 2021.
The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices rangingfrom $15.77 to $16.77 on January 3, 2022 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees.
On December 9, 2019, the Reporting Person was granted 65,000 restricted stock units, which vest with respect to 50% of the shares subject to the award on December 31, 2020 and with respect to the remaining 50% of the shares subject to the award on December 31, 2021, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan.